Le Centre Sud dans les médias
Un traité pour réorienter l’industrie pharmaceutique
Vers une recherche sans brevets
PAR GERMÁN VELÁSQUEZ
Face à la cupidité des laboratoires pharmaceutiques, un projet de traité international cherche à découpler le coût de la recherche et le prix des médicaments, afin de faciliter la découverte de remèdes efficaces et accessibles aux populations qui en ont le plus besoin. Même lorsqu’elles ne sont pas solvables. Certains mécanismes permettent d’ores et déjà d’orienter la recherche vers les maladies endémiques au Sud.
Le monde diplomatique
Disponible en version pdf ; ou à l’adresse : http://intra.mondediplo.net/fich.php/0c5657fb504c590/11_Sciences.pdf
SC verdict on Glivec has positive global implications: South Centre
The South Centre, an intergovernmental organisation of developing countries, has welcomed the recent ruling by the Supreme Court, dismissing the petition from Novartis on Glivec and has termed the verdict as a historic decision with positive global implications.
6 April 2013
Available at: www.pharmabiz.com/PrintArticle.aspx
South Centre hails Indian drug patent decision
From SOUTHNEWS, by Martin Khor:
“The ruling by the Supreme Court of India dismissing the petition from Novartis AG is a historic decision with positive global implications … The Novartis AG application had claimed a patent for a new salt form (imatinib mesylate), a medicine for the treatment of chronic myeloid leukemia. Novartis sells this medicine in several countries under the brand name Glivec (Gleevec). The Indian patent office had rejected the patent application on the ground that the claimed new form was anticipated in a US patent of 1996 for the compound imatinib and that the new form did not enhance the therapeutic efficacy of the drug. The decision was upheld by the Indian Patents Appellate Board (IPAB).
The decision by the Supreme Court of India has significant positive global implications. It has effectively protected the leading role of India in supplying affordable medicines to other developing countries. The reaffirmation of the primacy of health and access to medicines as a right of citizens is particularly important for the international community when these rights are under significant threat under bilateral trade and investment agreements.”
3 April 2013
Indian court rejects Novartis patent
German Velasquez, a special adviser for health and development at South Centre, a think tank based in Geneva, Switzerland, says he hopes that “many developing countries will follow India’s example to protect the rights of their populations to have access to essential medicines”. A 2011 study by South Centre found evidence of “a significant proliferation of patents on developments of incremental nature” in Argentina, Brazil, Colombia, India and South Africa.
1 April 2013
Concept Paper by South Centre on High Level Political Forum on Sustainable Development (HLPF)
1. Introduction: The HLPF is one of the most important outcomes of Rio+20, and perhaps its most important. It provides UN member states with the opportunity to set up an architecture that is effective and that can meet up to the present challenges in sustainable development (including the present multiple crises in the economic, social and environmental areas) and the even larger challenges that loom in the future. This concept note examines the functions mandated by Rio+20 for the HLPF and how these functions can be implemented, including the structural issues (high-level events, committees, secretariat, etc), the types of meetings and time required for them, the need for a dedicated body, the national and regional institutions and activities, and the arrangements for meeting the mandated functions. The areas required to be covered are many; this concept note is a preliminary attempt to provide views on some of the issues.
United Nations Sustainable Development Knowledge Platform
10 March 2013